i think obese people will want to get skinny i think health is something people care about and obsessed over i think more singles will live longer than married couples i think we will get lesser babies overtime.

Verdict: A demographic thesis worth watching — but the trade cannot be taken yet

The idea pairs a health-and-longevity demand thesis with a value screen across six names, and the strongest genuine anchor is that People Inc carries a 66.2% gross margin with $941M of cash while Live Oak generated $143.5M of fiscal-2025 free cash flow — real quality under the basket. But three of the six names show net insider selling per the June 30, 2026 filing period (LYV net sellers of roughly $26.2M, PPLI about $279 thousand, CARE about $232 thousand), Live Nation's fiscal-2025 diluted EPS was -$0.24 against $7.6B of long-term debt, and only Carter Bankshares has a rising dividend — Live Oak cut its payout from 12 cents to 9 cents in 2026. The setup is on a watch list, not a trade list: the rules were evaluated on real daily bars but did not fire in the 183 bars over the last nine months, no robust parameter setup was established, and the compiled entry thresholds are under repair. The fundamental trend is mixed rather than directional — Carter Bankshares EPS rose 30.2% year over year, but Health Catalyst still loses roughly 58 cents per revenue dollar and grew shares outstanding 1.15% quarter over quarter. The decision is to wait for published, reachable entry thresholds before sizing anything.

Trade now: no entry — the published conditions are out of range, and no robust setup has been established yet

There is nothing to trade today. All six entry conditions (CARE, HCAT, LIVE, LOB, LYV, PPLI) require both an ADX (14) above 1,000 and an RSI (14) below -1. The most oversold name in the basket is LIVE with an RSI of 15.1 at $7.80, and the farthest is HCAT at 69.0; every ADX reading sits between 7.9 (PPLI) and 38.5 (LYV). Those thresholds cannot be met by any real market — ADX is bounded near 100 and RSI between 0 and 100 — so the zero entries over the last 183 daily bars reflect the compiled thresholds rather than a genuinely rare setup. The research author has requested a bounded expanded search to find evaluable entry levels while keeping the symbols, long direction, exits, and risk rules intact. As of publication, that search has not produced a usable result: no robust parameter setup was established, and market-data gaps prevented the frozen rules from being evaluated at all. That is the one factual limitation that matters for the plan — you cannot size, stop, or target this idea in its current form because the entry levels themselves are under repair. What "wait" means concretely: do not enter any of the six names on this thesis today. The supporting risk framework is already defined — an 8.0% stop loss, a 15.0% take profit, roughly 2% risk per position and a maximum of about 16.7% of capital per name — so once revised entry thresholds are published, the trade will be actionable with pre-specified risk. Until then, the honest move is patience. Watch the RSI levels in the table below: if LIVE continues falling from its RSI of 15.1 or LYV breaks from 33.8, the strongest momentum-oversold candidates will be the first to hit any corrected entry zone.

Where a demographics/health thesis actually touches these six balance sheets

The idea argues demand for health, longevity, and changing household structure, paired with a value profile across six names (Carter Bankshares, Health Catalyst, LIVE Ventures, Live Oak Bancshares, Live Nation, and People Inc). On the fundamentals, the closest fundamental touchpoints are Health Catalyst and People Inc. Health Catalyst's net margin improved by roughly 99 percentage points quarter over quarter, from about -157% in the quarter ended March 31, 2026 to -57.5% in the quarter ended June 30, 2026, with operating margin improving by a similar 99 points. If health-data demand is strengthening, the direction of travel is at least consistent with it. People Inc is the purest health-adjacent holding: full-year revenue of $2.4B, a 66.2% gross margin (66th percentile among 766 IT peers), a current ratio of 2.75, and $941M in cash. Its Q2 net margin swung from -17.0% to +116.1% quarter over quarter, the single largest positive change in the group. For a value-oriented screen, positive free cash flow of $44.8M (61st percentile) alongside $1.4B of long-term debt is a tension, but the margin trajectory supports the demand narrative. The value angle also has genuine anchors. Live Oak generated $143.5M of free cash flow in its fiscal year ended December 31, 2025 — the 77th percentile of 877 financial-sector peers — with $864.9M in cash and a steady 3-cent quarterly dividend. Carter Bankshares posted diluted EPS of $1.38, up 30.2% year over year, with $39.9M of operating cash flow. These are the balance-sheet-quality facts the idea's 'value' profile depends on. Live Nation is the demand proxy in the group: fiscal 2025 revenue of $25.2B grew 8.8% year over year, with free cash flow of $333.6M (84th percentile among 170 communication-services peers) and a fiscal-year ROE of 183% — though that figure is inflated by a very thin equity base. On scope: the entry rules were evaluated on real daily bars but did not fire in the 183 evaluated bars over the last nine months, so this is a watch-list setup rather than an active signal; no robust parameter setup was established, and cross-stock correlation across the six names is covered in the dedicated section.

Deep losses, insider selling, and a rule set that has never fired

The bear case starts with the fact that several of these names are not 'value' at all — they are loss-makers. Health Catalyst reported a fiscal 2025 net loss of $178.0M on a net margin of -57.2%, an operating margin of -51.7% (19th percentile among 854 IT peers), a fiscal-year ROE of -72.4%, and free cash flow of just -$237,000. Even after the Q2 improvement, the company burned roughly 58 cents per revenue dollar in the most recent quarter. Its diluted share count has grown from 52.6M in fiscal 2021 to 69.9M, and shares outstanding rose another 1.15% quarter over quarter to 74.6M — continuous dilution sits directly against the idea's capital-allocation dimension. Ownership posture is adverse where it matters most. Live Nation insiders sold a net $26.2M in open-market transactions, reported for the period ended June 30, 2026 (a disclosure that passed its deadline before this analysis). Carter Bankshares insiders were net sellers of $231,898, and People Inc insiders sold a net $278,801, also per the June 30, 2026 filing period. That is three of six names with net insider selling, and by far the largest dollar amount sits at the group's largest company. Live Nation also carries $7.6B of long-term debt against just $271.0M of equity, with a current ratio below 1.0 and fiscal 2025 diluted EPS of -$0.24 — a far riskier balance sheet than the 'value' framing implies. Momentum and dividend evidence cut against the thesis too. LIVE Ventures' revenue fell 5.9% year over year to $444.9M, its quarterly results have swung to losses in three of the last four reported quarters (net losses in the quarters ended December 2025, March 2026, and June 2026), and it has no dividend. Health Catalyst, Live Nation, and People Inc pay no dividend. Live Oak cut its annual dividend from 12 cents to 9 cents in 2026 — a 25% reduction that a value thesis cannot easily absorb. Only Carter Bankshares has raised its payout, to 20 cents for 2026. Finally, the trading evidence gives the idea nothing to lean on yet: the entry conditions did not occur anywhere in the 183 daily bars evaluated over the…

Scores

• Conviction score breakdown: 30
• Thesis support: 45
• Trade readiness: 15
• Risk quality: 40
• Trigger proximity: 10
• Fundamentals trend: 40

Watch items

• CARE — RSI (14)
• HCAT — RSI (14)
• LIVE — RSI (14)
• LOB — RSI (14)
• LYV — RSI (14)
• PPLI — RSI (14)